Axsome Therapeutics, Inc. 8-K

What Happened

• Axsome Therapeutics (AXSM) announced on February 17, 2026 (via 8‑K and press release) that it entered a settlement agreement with Alkem Laboratories Ltd. resolving patent litigation in the U.S. District Court for the District of New Jersey concerning SUNOSI® (solriamfetol).
• Under the settlement, Axsome will grant Alkem a license to market a generic SUNOSI in the United States beginning on or after March 1, 2040 if no pediatric exclusivity is granted, or on or after September 1, 2040 if pediatric exclusivity is granted — in each case subject to FDA approval and customary conditions.

Key Details

• Parties: Axsome Therapeutics and Alkem Laboratories Ltd.; case pending in the U.S. District Court for the District of New Jersey.
• Generic launch timing: on or after March 1, 2040 (or on or after Sept 1, 2040 if pediatric exclusivity is granted).
• Conditions: Launch subject to FDA approval and customary contractual conditions and exceptions.
• Regulatory review: Settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
• Other litigation: Similar patent litigation by Axsome against another party relating to SUNOSI remains pending in the same court.

Why It Matters

• For investors, the settlement sets a defined, long-term potential timeline for generic competition to SUNOSI, which affects the product’s competitive exclusivity and revenue outlook through the 2030s.
• The timing is contingent on pediatric exclusivity and regulatory approvals, and the settlement still requires antitrust review, so outcomes and timing could change.
• The existence of other pending litigation means Axsome’s intellectual property position around SUNOSI is not fully resolved.